[go: up one dir, main page]

MXPA02006167A - Promocion de la angiogenesis con survivina. - Google Patents

Promocion de la angiogenesis con survivina.

Info

Publication number
MXPA02006167A
MXPA02006167A MXPA02006167A MXPA02006167A MXPA02006167A MX PA02006167 A MXPA02006167 A MX PA02006167A MX PA02006167 A MXPA02006167 A MX PA02006167A MX PA02006167 A MXPA02006167 A MX PA02006167A MX PA02006167 A MXPA02006167 A MX PA02006167A
Authority
MX
Mexico
Prior art keywords
survivin
angiogenesis
promotion
andor
expression
Prior art date
Application number
MXPA02006167A
Other languages
English (en)
Inventor
Dario C Altieria
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of MXPA02006167A publication Critical patent/MXPA02006167A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion describe los metodos para promover la angiogenesis utilizando agentes que incrementan la actividad, funcion y/o expresion de la survivina. La presente invencion tambien describe los metodos para inhibir la angiogenesis utilizando agentes que inhiben la actividad, la funcion y/o la expresion de la survivina.
MXPA02006167A 1999-12-21 2000-12-21 Promocion de la angiogenesis con survivina. MXPA02006167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17299199P 1999-12-21 1999-12-21
PCT/US2000/034663 WO2001046455A2 (en) 1999-12-21 2000-12-21 Survivin promotion of angiogenesis

Publications (1)

Publication Number Publication Date
MXPA02006167A true MXPA02006167A (es) 2004-02-26

Family

ID=22630045

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02006167A MXPA02006167A (es) 1999-12-21 2000-12-21 Promocion de la angiogenesis con survivina.

Country Status (6)

Country Link
EP (1) EP1242050A4 (es)
JP (1) JP2003529554A (es)
AU (1) AU2730801A (es)
CA (1) CA2393646A1 (es)
MX (1) MXPA02006167A (es)
WO (1) WO2001046455A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100820266B1 (ko) 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
AU2001275707A1 (en) * 2000-07-26 2002-02-05 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
KR101166214B1 (ko) 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법
SI1530636T1 (sl) 2002-08-21 2010-12-31 Stry Liaison Ofiice The University Of British Columbia Umiversity Indu Zdravljenje melanoma z zniĹľanjem nivojev klusterina
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
MXPA05011221A (es) * 2003-04-18 2006-02-17 Univ Pennsylvania Composiciones y metodos para la inhibicion de angiopoyetina 1 y 2 y su receptor tie2 por arnsi.
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
CA2586701C (en) 2004-11-09 2014-06-03 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
US8309351B2 (en) 2007-10-04 2012-11-13 Bionomics Limited Methods of identifying agents that inhibit angiogenesis
FR2932086A1 (fr) * 2008-06-06 2009-12-11 Lvmh Rech Methode de soin cosmetique anti-age par stimulation de l'expression de la survivine
CN109100288A (zh) 2013-03-15 2018-12-28 艾瑞思国际股份有限公司 用于血液样品中的粒子分析的鞘流体系统和方法
AU2016318158B2 (en) 2015-09-04 2022-09-15 Health Research, Inc. Anti-survivin antibodies for cancer therapy

Also Published As

Publication number Publication date
WO2001046455A3 (en) 2002-05-10
JP2003529554A (ja) 2003-10-07
CA2393646A1 (en) 2001-06-28
AU2730801A (en) 2001-07-03
EP1242050A4 (en) 2004-05-26
WO2001046455A2 (en) 2001-06-28
EP1242050A2 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
PL319605A1 (en) Novel benzoxazoles
MXPA02006167A (es) Promocion de la angiogenesis con survivina.
TR200000782T2 (tr) Resorsinol türevleri.
MY126559A (en) Fungicidal 2-methoxybenzophenones
DE69526790D1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
WO2001016114A3 (en) Heterocyclic compounds and methods for modulating cxcr3 function
BG105009A (en) Method for producing 4-carboxyamino-2-substituted 1,2,3,4-tetrahydroquinoline
MA24643A1 (fr) Tetrahydro-naphtalenes substitues et composes analogues
NO993350L (no) Vitronectin-reseptor-antagonister
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
MXPA01008347A (es) Compuestos quimicos.
EP1667685A4 (en) INHIBITORS OF QUINAZOLINE-BASED POTASSIUM CANAL
EP1667976A4 (en) Isoquinolinone POTASSIUM CHANNEL INHIBITORS
AP2001002220A0 (en) Calcilytic compounds.
NO985002D0 (no) FremgangsmÕte for mottaking, samt mottaker
BG107046A (en) Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
WO1998046632A3 (de) Inhibitoren für den urokinaserezeptor
MXPA05003315A (es) Un sistema de liberacion controlada que contiene temozolomida.
MXPA03010498A (es) Proceso para la preparacion de imipenem.
ZA200107985B (en) Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa.
IT242987Y1 (it) Guarnitura per mobili.
DE60000826D1 (de) 14.beta.,17-alpha-hydroxymethylandrostan derivate als androgene
PT1064265E (pt) Sintese de 3-amino-2-cloro-4-metilpiridina a partir de malononitrilo e acetona
GB2353794B (en) Deadplate assembly for I.S. machine
ATE275551T1 (de) Halogenpyrimidine